The Asia Pacific TB diagnostics market size is expected to reach a valuation of USD 644 million by 2030, growing at a CAGR of 5.7% during the forecast period (2022-2030). The bacteria Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.
Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent TB diagnostic procedure is a skin test; however, blood tests are becoming more widespread.
During the projected period, the Asia Pacific TB diagnostics and treatment market is expected to develop at a CAGR of roughly 2.8%. Asia had the highest number of new TB cases, accounting for 45% of all new cases. Tuberculosis incidence and mortality rates were shown to be greater in nations with poorer human development indexes, GDP per capita, corruption perception indexes, and populations receiving minimal food supplements. Among the health-system factors, governmental health spending per capita, total health spending per capita, increased water availability, hospital beds, and sanitation are all substantially linked to TB. Because Asia is home to most poor nations, the absence of these system characteristics raises TB rates across the Asia-Pacific area.
Get more information on this report Download Sample Report
Due to the high prevalence of TB and its quick spread in Asia-Pacific, the region is expected to expand profitably. The rising incidence of tuberculosis in Japan aids the expansion of the TB diagnostics industry, since the disease's high prevalence generates a pressing need for accurate and rapid diagnosis.
Only eight nations account for two-thirds of the world's TB sufferers. The top seven nations on the list are China, the Philippines, Indonesia, Pakistan, Bangladesh, Nigeria, and South Africa. Tuberculosis is a disease that affects people of all ages and from all walks of life. During the projection period, this increased prevalence is anticipated to have an influence on market growth.
The increased prevalence of TB among Japan's senior population is expected to fuel demand for tuberculosis diagnostics. The nations with the largest number of new TB cases and mortality rates also had the highest government health spending per capita, the lowest corruption perception score, and the fewest dietary supplements.
Lack of access to proper water, sanitation, and hospital beds is directly connected to tuberculosis. Because Asia-Pacific is still a growing region, all further amenities are not available. The market for TB diagnostics is growing as the prevalence of tuberculosis grows. This is a disadvantage for the TB diagnostics market.
Nucleic acid testing (NAT), skin test / Mantoux test (TST), blood test/serology tests, SMEAR microscopy, cultured-based tests, and radiography tests, among others, make up the TB diagnostics industry. The nucleic acid testing (NAT) category is estimated to lead the global market, with a CAGR of 5.91% to reach USD 561.32 million by 2030.
The use of nucleic acid amplification to identify and diagnose Mycobacterium tuberculosis has grown in popularity. Enzymatically amplified bacterial DNA (or ribosomal RNA translated into DNA) is detected using a signal-generating probe and a suitable reading device. Several commercially available enzymatic amplification methods are also available in markets across the world. Some of the most often used techniques include PCR (polymerase chain reaction), TMA (transcription-mediated amplification), and SDA (strand displacement amplification). The popularity of this NAT approach is expected to increase throughout the prediction period since it delivers exact TB detection.
According to the end-user, the Asia Pacific TB diagnostics market is divided into hospitals and diagnostic labs, physician's office laboratories, reference laboratories, and academics and research centres. The hospitals and diagnostic labs category is estimated to lead the worldwide market, with a CAGR of 5.87% to reach USD 934.93 million by 2030.
Country wise Growth Insights Request Sample Pages
Asia-Pacific is the second-largest market for TB diagnostics, with an anticipated market value of USD 644 million by 2030, representing a CAGR of 5.7%. Through 2028, the Asia Pacific TB diagnostics market is expected to grow at a rapid pace. The rising number of breakthroughs in the field of TB testing is responsible for this rise. From laboratory-based molecular diagnostics to AI (artificial intelligence) for CXR (chest x-ray) interpretation, there are several devices on the market. In 2021, the World Health Organization recommended CAD (computer-aided detection) of CXRs based on the findings of investigations conducted by Lunit in South Korea and Qure.ai in India. The market is growing due to improvements in healthcare infrastructure in Asian nations, a high prevalence of this condition in a few countries, and rising desire among individuals for improved treatment outcomes. According to a study published in BMJ Global Health in November 2020, TB infected an estimated 2.64 million Indians in 2019 and killed almost 450,000 people in India.